CONMED Corporation 2011 Q3 Form 10-Q Summary
Business Context and Reporting Period
CONMED is a medical technology company supplying surgical devices and equipment for minimally invasive procedures, including arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring, endosurgery and endoscopic technologies. The unaudited filing covers the three and nine months ended September 30, 2011, compared with the corresponding 2010 periods.
International sales represented approximately 49% of third-quarter revenue and 50% of nine-month revenue. The company sells both capital equipment and higher-volume single-use products.
Financial Performance and Key Metrics
| Metric | Q3 2011 | Q3 2010 | 9M 2011 | 9M 2010 |
|---|---|---|---|---|
| Net sales | $172.8 million | $172.2 million | $539.5 million | $529.6 million |
| Gross profit | $91.3 million | $89.0 million | $278.5 million | $274.5 million |
| Gross margin | 52.8% | 51.7% | 51.6% | 51.8% |
| Income from operations | $15.9 million | $15.2 million | $49.9 million | $43.5 million |
| Operating margin | 9.2% | 8.8% | 9.3% | 8.2% |
| Net income | $8.2 million | $8.8 million | $25.9 million | $23.4 million |
| Diluted EPS | $0.29 | $0.31 | $0.90 | $0.80 |
Q3 revenue increased 0.3%, while nine-month revenue increased 1.9%. Capital-equipment sales declined 7.0% in Q3 and 1.7% for the nine months; single-use product sales increased 2.6% and 2.9%, respectively. Management attributed weaker capital demand primarily to hospital purchasing constraints.
Q3 gross margin improved because of favorable foreign exchange, product mix and restructuring efficiencies. Nine-month gross margin declined slightly due primarily to unfavorable manufacturing production variances, partly offset by foreign exchange, mix and restructuring benefits.
Nine-month selling and administrative expense declined 0.9% despite approximately $5.4 million of unfavorable foreign-exchange impact. Research and development expense was essentially flat. The Q3 effective tax rate was 37.5%, versus 29.3% in 2010; the nine-month rate was 37.4%, versus 33.2%, primarily because 2010 included tax benefits related to the 2009 federal tax examination and research credit.
Cash Flow, Liquidity and Debt
- Cash provided by operating activities was $76.7 million for the first nine months of 2011, compared with $15.3 million in 2010. The comparison was affected by prior-year accounts-receivable-sale accounting and improved inventory management.
- Capital expenditures were $12.7 million, compared with $10.9 million in 2010; management expected approximately $17.0 million for full-year 2011.
- Cash and cash equivalents increased to $39.9 million at September 30, 2011, from $12.4 million at December 31, 2010.
- At September 30, 2011, the company reported $166.4 million of current debt and $9.1 million of long-term debt on the balance sheet. Principal obligations included $53.9 million outstanding under the senior credit agreement term loan, a $10.0 million mortgage note and $112.1 million of 2.50% convertible senior subordinated notes due 2024.
- No borrowings were outstanding under the $250.0 million revolving credit facility. Available borrowing capacity was $240.2 million after approximately $9.8 million reserved for letters of credit.
- The convertible notes were classified as current because holders could put them to the company on November 15, 2011. Management expected most notes to be put and planned to use the undrawn revolving facility to fund repurchases.
- The company was in compliance with its credit-agreement covenants at September 30, 2011.
Material Changes Versus the Prior Comparable Period
- Q3 net income declined 6.2% despite higher operating income, primarily because the effective tax rate increased substantially.
- Nine-month net income rose 10.7%, and diluted EPS increased from $0.80 to $0.90.
- The aggregated Linvatec, Electrosurgery and Endosurgery segment increased Q3 sales 1.2% and operating margin from 14.0% to 14.9%; nine-month operating margin increased from 13.2% to 14.6%.
- Patient Care remained weak: Q3 sales declined 6.1% and operating margin fell to negative 5.1%; nine-month sales declined 4.5% and operating margin fell from 2.3% to negative 5.2%.
- Endoscopic Technologies Q3 sales declined 1.6%, but operating margin improved from 0.9% to 4.2%. Nine-month operating margin improved from 0.2% to 1.9%.
- The company repurchased $15.0 million of common stock during the first nine months, including 669,241 shares during Q3. In October 2011, the board authorized an additional $100.0 million repurchase authorization, bringing aggregate remaining authorization to $108.8 million.
Guidance, Outlook, Risks and Unusual Items
- Management was cautiously optimistic about improving global economic conditions but noted continued volatility, hospital capital-spending constraints and foreign-exchange exposure.
- Restructuring costs were $2.6 million in cost of sales and $0.8 million in other expense during the first nine months. Management estimated total 2011 restructuring costs of approximately $4.0 million to $5.0 million, with additional charges possible.
- Management identified Patient Care goodwill as potentially vulnerable to impairment in future periods, although no triggering event or impairment was identified at the filing date.
- Key risks include economic conditions, foreign exchange and interest rates, customer purchasing patterns, competition, product acceptance, acquisitions, materials costs, regulatory actions, product recalls, patent and other litigation, and future debt and capital-spending requirements.
- Pending legal matters include ordinary-course product liability, patent, regulatory and governmental claims. Management did not expect current matters to have a material adverse effect, but noted that future claims could exceed insurance or reserves. Product-liability insurance was $25 million per incident and in the annual aggregate.
- The company used foreign-exchange forward contracts for risk management. Hedged-contract notional amounts totaled $80.4 million at September 30, 2011, with approximately $2.3 million of net unrealized gains in accumulated other comprehensive income.
- Management stated that operating cash flow, cash on hand and available revolver capacity should cover working capital, debt service, capital expenditures and planned share repurchases for the foreseeable future.
Most Important Facts to Verify
- Whether holders put the expected majority of the $112.1 million convertible notes on November 15, 2011 and the resulting impact on debt, interest expense and revolver utilization.
- Whether Patient Care revenue and profitability recover sufficiently to avoid a future goodwill impairment.
- Actual full-year restructuring costs versus the $4.0 million to $5.0 million estimate and the realization of related cost savings.
- Whether hospital capital-equipment demand improves and offsets continued weakness in capital sales.
- The effect of foreign-exchange movements on revenue, gross margin, operating expenses and comprehensive income.
- Progress in addressing the Patient Care segment’s negative operating margin and declining sales.
- Future cash deployment among debt repayment, note repurchases, capital expenditures and the expanded share-repurchase program.